Table 4 Factors that affects the diffusion of NCE products: Panel regression results for all therapeutic groups
From: Differential diffusion of pharmaceutical innovations in a mixed market middle - income economy
Model 1 | Model 2(a) and Model 2(b) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | Â | Â | Public | Private | ||||
Variable | Coefficient | Â | Standard Error | Variable | Coefficient | Â | Standard Error | Coefficient | Â | Standard Error |
Intercept | 0.964 | Â | (1.433) | Intercept | 1.926 | Â | (1.456) | -1.499 | *** | (2.426) |
Drug characteristic | ||||||||||
 ln price per DDD | -1.326 | ** | (0.489) | ln price per DDD | -1.874 | *** | (0.473) | -0.291 | *** | (0.858) |
Structure and environment characteristics | ||||||||||
 Generic share (DDD) | -1.237 | * | (0.490) | Generic share (DDD) | -2.390 | *** | (0.583) | 0.131 |  | (0.625) |
 Market concentration (HHI) | -1.383 | * | (0.553) | Market concentration (HHI) | -1.305 |  | (0.723) | -1.773 | * | (0.870) |
Year after Registration | ||||||||||
 Year 1 | 1.467 | *** | (0.189) | Year 1 | 1.222 | *** | (0.295) | 1.596 | *** | (0.187) |
 Year 2 | 2.347 | *** | (0.205) | Year 2 | 2.299 | *** | (0.309) | 2.313 | *** | (0.198) |
 Year 3 | 2.685 | *** | (0.216) | Year 3 | 2.843 | *** | (0.324) | 2.440 | *** | (0.213) |
 Year 4 | 2.944 | *** | (0.232) | Year 4 | 3.194 | *** | (0.338) | 2.604 | *** | (0.221) |
 Year 5 | 3.126 | *** | (0.234) | Year 5 | 3.313 | *** | (0.343) | 2.915 | *** | (0.233) |
R - squared | 0.610 | Â | Â | R - squared | 0.529 | Â | Â | 0.344 | Â | Â |
Corr (u_i, Xb) | -0.424 | Â | Â | Corr (u_i, Xb) | -0.802 | Â | Â | 0.305 | Â | Â |
Rho | 0.863 | Â | Â | Rho | 0.938 | Â | Â | 0.917 | Â | Â |
Number of observations | 1,146 | Â | Â | Number of observations | 531 | Â | Â | 615 | Â | Â |